Fred Hutchinson Cancer Center.

Clinical research site in Seattle, Washington · 825 EASTLAKE AVE E, SEATTLE, WA 98109-4405 · (206) 606-7222 · Website

Part of Fred Hutchinson Cancer Center

As of July 2026, 213 paid clinical trials are recruiting at Fred Hutchinson Cancer Center. in Seattle, Washington. Active studies at this site cover conditions such as Breast Cancer, Colorectal Cancer and Acute Myeloid Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Fred Hutchinson Cancer Center. (213)

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma

61 locations incl. Los Angeles

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07392892·Phase 2, Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

for Adenovirus Infections

26 locations incl. Phoenix

Sponsor: SymBio Pharmaceuticals

Sex: All·Age: 2 Months+

Code: NCT07387367·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

for Intestinal Neoplasms

166 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222800·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

for Carcinoma, Hepatocellular

29 locations incl. Los Angeles

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227012·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

for Prostatic Neoplasms, Castration-Resistant

49 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07225946·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for Ovarian Neoplasms

88 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07213804·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

for Ovarian Cancer

38 locations incl. Anchorage

Sponsor: Incyte Corporation

Sex: Female·Age: 18+

Code: NCT07214779·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for Metastatic Castration-resistant Prostate Neoplasms

53 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

for Breast Cancer

102 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07062965·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

169 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for Breast Neoplasms

59 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06966700·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

for Metastatic Castration-Resistant Prostate Cancer

44 locations incl. Chandler

Sponsor: Pfizer

Sex: Male·Age: 18+

Code: NCT06629779·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

for Breast Neoplasms

39 locations incl. Birmingham

Sponsor: Natera, Inc.

Sex: All·Age: 18+

Code: NCT07214532·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

68 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

79 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

for Urothelial Cancer

33 locations incl. Gilbert

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07106762·Phase 2, Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

for Colon Adenocarcinoma

31 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06997497·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

for Chronic Lymphocytic Leukemia

37 locations incl. Birmingham

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06973187·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

77 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

for Solid Tumors

43 locations incl. Tucson

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT03486873·Phase 3·Recruiting·Listed Apr 2018

Apply to this trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for Triple Negative Breast Neoplasms

37 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

for Cachexia

81 locations incl. Birmingham

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06989437·Phase 2, Phase 3·Recruiting·Listed May 2025

Apply to this trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

26 locations incl. Cerritos

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

for Leukemia, Myeloid, Acute

51 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06852222·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

58 locations incl. Anchorage

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

27 locations incl. Phoenix

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT05650632·Phase 1·Recruiting·Listed Dec 2022

Apply to this trial

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

for Pancreatic Neuroendocrine Tumor (pNET)

40 locations incl. Birmingham

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT06943755·Phase 2, Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

for Metastatic Non-small Cell Lung Cancer With MTAP Deletion

39 locations incl. Anchorage

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07063745·Phase 2, Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

for Melanoma

58 locations incl. Birmingham

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05538130·Phase 1·Recruiting·Listed Sep 2022

Apply to this trial

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

for Prostate Cancer

49 locations incl. Phoenix

Sponsor: Merck Sharp & Dohme LLC

Sex: Male·Age: 18+

Code: NCT06925737·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

for Glioma

42 locations incl. Birmingham

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT05303519·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

for Pancreatic Ductal Adenocarcinoma

25 locations incl. Duarte

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06586515·Phase 1·Recruiting·Listed Sep 2024

Apply to this trial

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

for Non-Small Cell Lung Cancer, NSCLC

28 locations incl. Gilbert

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06162221·Phase 1, Phase 2·Recruiting·Listed Dec 2023

Apply to this trial

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

for Triple Negative Breast Cancer

26 locations incl. Phoenix

Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05377996·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

for Endometrial Adenocarcinoma

42 locations incl. Phoenix

Sponsor: Acrivon Therapeutics

Sex: Female·Age: 18+

Code: NCT05548296·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

for Urothelial Carcinoma

144 locations incl. Gilbert

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04879329·Phase 2·Recruiting·Listed May 2021

Apply to this trial

DALY II USA/ MB-CART2019.1 for DLBCL

for Refractory Diffuse Large B Cell Lymphoma (DLBCL)

28 locations incl. Birmingham

Sponsor: Miltenyi Biomedicine GmbH

Sex: All·Age: 18+

Code: NCT04792489·Phase 2·Recruiting·Listed Mar 2021

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

for Muscle-invasive Urothelial Carcinoma

9 locations incl. Basking Ridge

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06534983·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

for Melanoma, Cutaneous Malignant

37 locations incl. Phoenix

Sponsor: Immatics US, Inc.

Sex: All·Age: 18+

Code: NCT06743126·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Showing the 40 most relevant of 213 recruiting trials at this site. Browse all with filters →

More research sites in Seattle

Seattle Children's Hospital (192 trials)
University of Washington (186 trials)
Fred Hutchinson Cancer Center (142 trials)
Fred Hutch/University of Washington Cancer Consortium (104 trials)
Swedish Medical Center-First Hill (66 trials)
University of Washington Medical Center (48 trials)
Swedish Medical Center (41 trials)
University of Washington Medical Center - Montlake (38 trials)
Swedish Cancer Institute (37 trials)
Fred Hutchinson Cancer Research Center (36 trials)

Explore more

Paid clinical trials in Seattle, WA · Washington clinical trials